ARCA biopharma, Inc. (ABIO)
- GlobeNewswire
ARCA biopharma Announces Second Quarter 2022 Financial Results
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr
- Simply Wall St.
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cab
